Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid…

thAnnual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas.The data will be presented in a poster: Title: Breaking barriers in solid tumors with SMART allogeneic CAR T-cellsDate / Time:November 9 th, 2024 from 9:00am to 8:30pm ET Presenter:Beatriz Aranda-Orgilles, Associate Director, Immuno Oncology at Cellectis Poster number:254Despite the success of CAR T-cell therapies treating blood cancers, these cutting-edge technologies continue to...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at…

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will...

Women's Health Market is expected to generate a revenue of USD 65.23 Billion by…

The global focus on women's health has never been more prominent. With rising investments in healthcare innovations, greater awareness of gender-specific healthcare needs, and the ongoing push toward personalized care, this market is poised for accelerated growth. Verified Market Research®'s new report identifies the challenges, trends, and opportunities critical to industry leaders aiming to harness this growth. The global focus on women's health has never been more prominent. With rising...

Roche to present new and encouraging long-term follow-up data across broad…

thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab) as well as new investigational combination data.Key presentations include: Five-year data from the phase III POLARIX study (abstract #469) reinforce the potential of...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 5 November 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...

Coloplast Finance B.V. - Annual Report, 2023/24

Hereby please find the Annual Report 2023/24 for the group of Coloplast A/S. Attachment 07_2024_Annual_Report_2023-24

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent…

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington's disease progression and reductions in key biomarker of neurodegeneration ~~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First...

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate…

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease (PD) on track to report interim safety and immunogenicity dataPrescreening rate for Phase 2b Retain trial of JNJ-2056 (ACI-35.030) in Alzheimer's disease (AD) triggered CHF 24.6 million milestone under agreementJNJ-2056 received Fast Track designation from the U.S. FDACash of CHF 157.9 million at the end of September, plus the CHF 24...

Particle Counters Market to Hit USD 986.3 Million by 2029 with 9.5% CAGR |…

Technical limitations such as producing false results due to environmental factors like humidity and temperature are amongst key factors that technically limit their use among the end-user segments. Alternate options, like particle analyzers offering both analysis and counting, such offerings may reduce the TAM for particle counters. High initial deployment costs and periodic calibration and maintenance sessions lead to frequent performance downtimes, resulting in increased operating costs. All…

Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial…

ENDOTHIRD-QUARTER FINANCIAL PERFORMANCE(in thousands) ENDOTHIRD-QUARTER FINANCIAL PERFORMANCE (in thousands) CONSOLIDATED RESULTS Total revenues in third-quarter 2024 were$427 million, a decrease of 6% compared to$452 millionin third-quarter 2023. This decrease was primarily attributable to competitive pressure across the Generic Pharmaceuticals and Sterile Injectables segments which was partially offset by Branded Pharmaceuticals segment revenue growth. Net Loss in...

Rhino Rescue Empowers First Aid Training Program in Mexico, Further Elevating…

According to data from the World Health Organization (WHO), Interpersonal violence and Road injuries continue to be the leading causes of death in Mexico, accounting for 30.3% and 12.3% respectively. Over the past 20 years, an average of 15,700 Mexicans have lost their lives annually due to injuries sustained in traffic accidents. The efficiency of first aid is crucial in these emergencies. According to data from theWorld Health Organization (WHO), Interpersonal violence and Road injuries...

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating…

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers NCT06555744 ) to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced folate receptor-⍺ (FR⍺)-expressing solid tumors including ovarian, endometrial, and non-small cell lung (NSCLC) cancers.“Our team is excited to initiate this important clinical trial to assess the...

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Precision Medicine Redefined: AI Meets Multi-Omics Precision Medicine Redefined: AI Meets Multi-Omics JINTS BIOis at the forefront of developing personalized lung cancer therapies through the integration of artificial intelligence and multi-omics technology. Multi-omics offers a comprehensive approach to disease biology by combining genomics, transcriptomics, metabolomics, and proteomics. Using AI and national supercomputing infrastructure, the project aims to enhance drug efficacy...

Sanitas, one of Switzerland's largest health insurers, embeds Lifelight's vital…

Now with the inclusion of Lifelight, Sanitas is taking a proactive approach to further mitigate health risks. A chronic illness guide within the app focuses on prevention, detection and management of cardiovascular disease (CVD) through early monitoring and pre-emptive intervention. Now with the inclusion of Lifelight, Sanitas is taking a proactive approach to further mitigate health risks. A chronic illness guide within the app focuses on prevention, detection and management of...

Xeltis expands leadership team with appointment of Luc Verhees as Vice President…

Eliane Schutte, Chief Executive Officer, Xeltis commented: "As we progress our clinical programs and push towards commercializing aXess, Luc brings great knowledge and familiarity of the clinical trials landscape across multiple continents. Luc's skills and track record will be invaluable as we prepare to initiate our US pivotal trial for aXess." Eliane Schutte, Chief Executive Officer, Xeltis commented : "As we progress our clinical programs and push towards commercializing…

INTRODUCING JUICE PLUS+ LUMINATE: ONE OF THE FIRST, RAPID ACTING, PLANT-BASED…

In today's fast-paced world, the pressures of daily life can take a toll on our cognitive function, leading to fatigue and challenges concentrating. New consumer research by Juice Plus+ that polled over 12,000 people[6], uncovered a growing trend in procrastination, with nearly 78% experiencing difficulty keeping focused on tasks. The data also found that people are spending over 5 hours of the day unfocused. Whether managing a demanding workload, studying for long hours, or balancing...

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin 1. Reported revenue in DKK grew 10% to DKK 27,030 million.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations...

Coloplast A/S - Full-Year Financial Results 2023/24

2023/24 Announcement of full-year financial results1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin 1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months).Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings...

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive…

Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.“We have entered the final year of our 2025 strategy. In this strategic period, Coloplast has made significant investments to expand the reach of the company and build four growth platforms, Chronic Care, Voice & Respiratory Care, Advanced Wound Care and Interventional Urology, which must drive value creation in the years...

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid…

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at…

Lenzing Nonwovens expands its LENZING™ Lyocell Dry fiber portfolio to offer…

Genmab to Present at Jefferies London Healthcare Conference

At 11.1% CAGR Aesthetic Medical Devices Market Size to Reach $44.60 Billion By…

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp…

The Rise of Thermostatic Mixers Market: A $5.79 Billion Industry Dominated by…

Women's Health Market is expected to generate a revenue of USD 65.23 Billion by…

Roche to present new and encouraging long-term follow-up data across broad…

Novo Nordisk A/S - share repurchase programme

Coloplast Finance B.V. - Annual Report, 2023/24

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent…

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate…

Particle Counters Market to Hit USD 986.3 Million by 2029 with 9.5% CAGR |…

Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial…

Rhino Rescue Empowers First Aid Training Program in Mexico, Further Elevating…

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating…

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Sanitas, one of Switzerland's largest health insurers, embeds Lifelight's vital…

Xeltis expands leadership team with appointment of Luc Verhees as Vice President…

INTRODUCING JUICE PLUS+ LUMINATE: ONE OF THE FIRST, RAPID ACTING, PLANT-BASED…

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Full-Year Financial Results 2023/24

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive…